An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Cultures and Establishment of FLT3 Inhibitor-Resistant Cell Lines
2.2. Sanger Sequencing and Allele-Specific PCR of FLT3
2.3. Cell Growth Assay and Apoptosis Assay
2.4. Flow Cytometry Analysis of FLT3 Expression
2.5. Immunoprecipitation and Immunoblot Analysis
3. Results
3.1. Establishment of MOLM-13 Sublines with a Resistance Mutation to an FLT3-Selective Inhibitor
3.2. Combination Treatment of FI-700 and 17-AAG Synergistically Inhibited the Growth of Parent and FLT3 Inhibitor-Resistant MOLM-13 Cells
3.3. Combination of FI-700 and 17-AAG Inhibited FLT3 Signaling in FLT3 Inhibitor-Resistant MOLM-13 Cells
3.4. Combination of 17-AAG and FI-700 Inhibited the Association of HSP90 and FLT3
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rosnet, O.; Matteï, M.-G.; Marchetto, S.; Birnbaum, D. Isolation and Chromosomal Localization of a Novel FMS-like Tyrosine Kinase Gene. Genomics 1991, 9, 380–385. [Google Scholar] [CrossRef]
- Rosnet, O.; Schiff, C.; Pébusque, M.-J.; Marchetto, S.; Tonnelle, C.; Toiron, Y.; Birg, F.; Birnbaum, D. Human FLT3/FLK2 Gene: CDNA Cloning and Expression in Hematopoietic Cells. Blood 1993, 82, 1110–1119. [Google Scholar] [CrossRef] [PubMed]
- Lemmon, M.A.; Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell 2010, 141, 1117–1134. [Google Scholar] [CrossRef] [PubMed]
- Kiyoi, H.; Naoe, T. Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with Flt3 Mutation. Int. J. Hematol. 2006, 83, 301–308. [Google Scholar] [CrossRef] [PubMed]
- Kihara, R.; Nagata, Y.; Kiyoi, H.; Kato, T.; Yamamoto, E.; Suzuki, K.; Chen, F.; Asou, N.; Ohtake, S.; Miyawaki, S.; et al. Comprehensive Analysis of Genetic Alterations and Their Prognostic Impacts in Adult Acute Myeloid Leukemia Patients. Leukemia 2014, 28, 1586–1595. [Google Scholar] [CrossRef]
- Ley, T.; Miller, C.; Ding, L.; Raphael, B.; Mungall, A.; Robertson, G.; Hoadley, K.; Triche, T.; Laird, P.; Baty, J.; et al. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med. 2013, 368, 2059–2074. [Google Scholar]
- Hochhaus, A.; Baccarani, M.; Silver, R.T.; Schiffer, C.; Apperley, J.F.; Cervantes, F.; Clark, R.E.; Cortes, J.E.; Deininger, M.W.; Guilhot, F.; et al. European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia 2020, 34, 966–984. [Google Scholar] [CrossRef]
- Stone, R.M.; Mandrekar, S.J.; Sanford, B.L.; Laumann, K.; Geyer, S.; Bloomfield, C.D.; Thiede, C.; Prior, T.W.; Döhner, K.; Marcucci, G.; et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl. J. Med. 2017, 377, 454–464. [Google Scholar] [CrossRef]
- Perl, A.E.; Martinelli, G.; Cortes, J.E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M.R.; Larson, R.A.; Ustun, C.; et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019, 381, 1728–1740. [Google Scholar] [CrossRef]
- Cortes, J.E.; Khaled, S.; Martinelli, G.; Perl, A.E.; Ganguly, S.; Russell, N.; Krämer, A.; Dombret, H.; Hogge, D.; Jonas, B.A.; et al. Quizartinib versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet Oncol. 2019, 20, 984–997. [Google Scholar] [CrossRef]
- Wandinger, S.K.; Richter, K.; Buchner, J. The Hsp90 Chaperone Machinery*. J. Biol. Chem. 2008, 283, 18473–18477. [Google Scholar] [CrossRef]
- Butler, L.M.; Ferraldeschi, R.; Armstrong, H.K.; Centenera, M.M.; Workman, P. Maximizing the Therapeutic Potential of HSP90 Inhibitors. Mol. Cancer Res. 2015, 13, 1445–1451. [Google Scholar] [CrossRef]
- Isaacs, J.S.; Xu, W.; Neckers, L. Heat Shock Protein 90 as a Molecular Target for Cancer Therapeutics. Cancer Cell 2003, 3, 213–217. [Google Scholar] [CrossRef]
- Solárová, Z.; Mojžiš, J.; Solár, P. Hsp90 Inhibitor as a Sensitizer of Cancer Cells to Different Therapies (Review). Int. J. Oncol. 2015, 46, 907–926. [Google Scholar]
- Prodromou, C.; Roe, S.M.; O’Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone. Cell 1997, 90, 65–75. [Google Scholar] [CrossRef] [PubMed]
- Kiyoi, H.; Shiotsu, Y.; Ozeki, K.; Yamaji, S.; Kosugi, H.; Umehara, H.; Shimizu, M.; Arai, H.; Ishii, K.; Akinaga, S.; et al. A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations. Clin. Cancer Res. 2007, 13, 4575–4582. [Google Scholar] [CrossRef] [PubMed]
- Döhner, H.; Wei, A.H.; Appelbaum, F.R.; Craddock, C.; DiNardo, C.D.; Dombret, H.; Ebert, B.L.; Fenaux, P.; Godley, L.A.; Hasserjian, R.P.; et al. Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN. Blood 2022, 140, 1345–1377. [Google Scholar] [CrossRef]
- Minami, Y.; Kiyoi, H.; Yamamoto, Y.; Yamamoto, K.; Ueda, R.; Saito, H.; Naoe, T. Selective Apoptosis of Tandemly Duplicated FLT3-Transformed Leukemia Cells by Hsp90 Inhibitors. Leukemia 2002, 16, 1535–1540. [Google Scholar] [CrossRef] [PubMed]
- Yao, Q.; Nishiuchi, R.; Li, Q.; Kumar, A.R.; Hudson, W.A.; Kersey, J.H. FLT3 Expressing Leukemias Are Selectively Sensitive to Inhibitors of the Molecular Chaperone Heat Shock Protein 90 through Destabilization of Signal Transduction-Associated Kinases. Clin. Cancer Res. 2003, 9, 4483–4493. [Google Scholar] [PubMed]
- Al Shaer, L.; Walsby, E.; Gilkes, A.; Tonks, A.; Walsh, V.; Mills, K.; Burnett, A.; Rowntree, C. Heat Shock Protein 90 Inhibition Is Cytotoxic to Primary AML Cells Expressing Mutant FLT3 and Results in Altered Downstream Signalling. Br. J. Haematol. 2008, 141, 483–493. [Google Scholar] [CrossRef]
- Yu, C.; Kancha, R.K.; Duyster, J. Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations. PLoS ONE 2014, 9, e97116. [Google Scholar]
- George, P.; Bali, P.; Cohen, P.; Tao, J.; Guo, F.; Sigua, C.; Vishvanath, A.; Fiskus, W.; Scuto, A.; Annavarapu, S.; et al. Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3. Cancer Res. 2004, 64, 3645–3652. [Google Scholar] [PubMed]
- Yao, Q.; Nishiuchi, R.; Kitamura, T.; Kersey, J.H. Human Leukemias with Mutated FLT3 Kinase Are Synergistically Sensitive to FLT3 and Hsp90 Inhibitors: The Key Role of the STAT5 Signal Transduction Pathway. Leukemia 2005, 19, 1605–1612. [Google Scholar] [PubMed]
- Katayama, K.; Noguchi, K.; Sugimoto, Y. Heat Shock Protein 90 Inhibitors Overcome the Resistance to Fms-like Tyrosine Kinase 3 Inhibitors in Acute Myeloid Leukemia. Oncotarget 2018, 9, 34240. [Google Scholar] [PubMed]
- Eguchi, M.; Minami, Y.; Kuzume, A.; Chi, S. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines 2020, 8, 245. [Google Scholar] [CrossRef]
- Opatz, S.; Polzer, H.; Herold, T.; Konstandin, N.P.; Ksienzyk, B.; Zellmeier, E.; Vosberg, S.; Graf, A.; Krebs, S.; Blum, H.; et al. Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core-Binding Factor Leukemia. Blood 2013, 122, 1761–1769. [Google Scholar] [CrossRef]
- Huang, K.; Yang, M.; Pan, Z.; Heidel, F.H.; Scherr, M.; Eder, M.; Fischer, T.; Büsche, G.; Welte, K.; von Neuhoff, N.; et al. Leukemogenic Potency of the Novel FLT3-N676K Mutant. Ann. Hematol. 2016, 95, 783–791. [Google Scholar] [CrossRef]
- Tarver, T.C.; Hill, J.E.; Rahmat, L.; Perl, A.E.; Bahceci, E.; Mori, K.; Smith, C.C. Gilteritinib Is a Clinically Active FLT3 Inhibitor with Broad Activity against FLT3 Kinase Domain Mutations. Blood Adv. 2020, 4, 514–524. [Google Scholar] [CrossRef]
- Ren, X.; Li, T.; Zhang, W.; Yang, X. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy. Cells 2022, 11, 2556. [Google Scholar]
- Burd, A.; Levine, R.L.; Ruppert, A.S.; Mims, A.S.; Borate, U.; Stein, E.M.; Patel, P.; Baer, M.R.; Stock, W.; Deininger, M.; et al. Precision Medicine Treatment in Acute Myeloid Leukemia Using Prospective Genomic Profiling: Feasibility and Preliminary Efficacy of the Beat AML Master Trial. Nat. Med. 2020, 26, 1852–1858. [Google Scholar]
- Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 2016, 374, 2209–2221. [Google Scholar] [CrossRef]
- Hosono, N.; Yamauchi, T.; Chi, S.; Fukushima, K.; Shibayama, H.; Katagiri, S.; Gotoh, A.; Eguchi, M.; Morishita, T.; Ogasawara, R.; et al. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. Blood 2021, 138, 4457. [Google Scholar]
- Katagiri, S.; Chi, S.; Minami, Y.; Fukushima, K.; Shibayama, H.; Hosono, N.; Yamauchi, T.; Morishita, T.; Kondo, T.; Yanada, M.; et al. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia. Int. J. Mol. Sci. 2022, 23, 4694. [Google Scholar] [PubMed]
- Ishikawa, Y.; Kawashima, N.; Atsuta, Y.; Sugiura, I.; Sawa, M.; Dobashi, N.; Yokoyama, H.; Doki, N.; Tomita, A.; Kiguchi, T.; et al. Prospective Evaluation of Prognostic Impact of KIT Mutations on Acute Myeloid Leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020, 4, 66–75. [Google Scholar]
- Tsujimura, A.; Kiyoi, H.; Shiotsu, Y.; Ishikawa, Y.; Mori, Y.; Ishida, H.; Toki, T.; Ito, E.; Naoe, T. Selective KIT Inhibitor KI-328 and HSP90 Inhibitor Show Different Potency against the Type of KIT Mutations Recurrently Identified in Acute Myeloid Leukemia. Int. J. Hematol. 2010, 92, 624–633. [Google Scholar] [PubMed]
- Yu, W.; Wang, J.; Jin, J.; Qian, W.; Qian, J.; Cheng, Y.; Wang, L. Heat Shock Protein 90 Inhibition Results in Altered Downstream Signaling of Mutant KIT and Exerts Synergistic Effects on Kasumi-1 Cells When Combining with Histone Deacetylase Inhibitor. Leuk. Res. 2011, 35, 1212–1218. [Google Scholar] [CrossRef]
- Saito, Y.; Takahashi, T.; Obata, Y.; Nishida, T.; Ohkubo, S.; Nakagawa, F.; Serada, S.; Fujimoto, M.; Ohkawara, T.; Nishigaki, T.; et al. TAS-116 Inhibits Oncogenic KIT Signalling on the Golgi in Both Imatinib-Naïve and Imatinib-Resistant Gastrointestinal Stromal Tumours. Br. J. Cancer 2020, 122, 658–667. [Google Scholar]
- Kurokawa, Y.; Honma, Y.; Sawaki, A.; Naito, Y.; Iwagami, S.; Komatsu, Y.; Takahashi, T.; Nishida, T.; Doi, T. Pimitespib in Patients with Advanced Gastrointestinal Stromal Tumor (CHAPTER-GIST-301): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Ann. Oncol. 2022, 33, 959–967. [Google Scholar]
- Ohkubo, S.; Kodama, Y.; Muraoka, H.; Hitotsumachi, H.; Yoshimura, C.; Kitade, M.; Hashimoto, A.; Ito, K.; Gomori, A.; Takahashi, K.; et al. TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models. Mol. Cancer Ther. 2015, 14, 14–22. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ogata, H.; Minami, Y. An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation. Int. J. Transl. Med. 2023, 3, 389-398. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm3030027
Ogata H, Minami Y. An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation. International Journal of Translational Medicine. 2023; 3(3):389-398. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm3030027
Chicago/Turabian StyleOgata, Hiraku, and Yosuke Minami. 2023. "An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation" International Journal of Translational Medicine 3, no. 3: 389-398. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm3030027